Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes

ConclusionThis analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.Clinical Trial Registration NumberNCT03061214.

Source: Diabetes Therapy - January 18, 2024 Category: Endocrinology Source Type: research